The Comments Are In: Stakeholders Categorize Genomic Tests


This is the third white paper in a series documenting Medicare’s efforts to begin using 100-­-plus new CPT codes for molecular diagnostic tests. The codes were approved by the AMA CPT editorial panel in October 2010 and February 2011, allowing publication in October 2011 for use on January 1, 2012.

The first white paper, “Tempest in the Melting Pot: Genomics Reimbursement 2012,” appeared in November 2011 and described Medicare’s decision to defer use of the CPT codes until 2013. The second white paper, “Tempest Continues: Fee Schedules in Collision,” appeared in July 2012 and described Medicare’s dilemma, by then already a year old, in assigning the genetic codes to the clinical laboratory or the physician fee schedule. This third white paper, appearing in September 2012, discusses the broad range of stakeholder comments received by CMS. These public comments will inform the decision that CMS will announce in the first week of November, 2012.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP | Attorney Advertising

Written by:


Foley Hoag LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.